SCHEMBL943234

SCHEMBL943234

O=C(O)c1c(O)cccc1CCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC28A3 Q9HAS3 2/20 0.57
MAOB P27338 1/20 0.53
SLC5A1 P13866 1/20 0.51
PTPN1 P18031 1/20 0.49
SYNJ2 O15056 2/20 0.45
HIF1A Q16665 1/20 0.45
KDM4E B2RXH2 1/20 0.45
ABL1 P00519 1/20 0.45
ALPL P05186 1/20 0.45
POLB P06746 1/20 0.45
ALPI P09923 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
ALPG P10696 1/20 0.45
PABPC1 P11940 1/20 0.45
RECQL P46063 1/20 0.45
GALK1 P51570 1/20 0.45
CASP7 P55210 1/20 0.45
CASP6 P55212 1/20 0.45
MCL1 Q07820 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL942069 0.93 SLC28A3 (0.55) SLC28A3MAOBSLC5A1PTPN1MCL1
SCHEMBL940441 0.90 SLC28A3 (0.60) SLC28A3SLC5A1PTPN1SYNJ2HIF1A
SCHEMBL28720616 0.84 MAOB (0.54) SLC28A3MAOBSLC5A1PTPN1
SCHEMBL941047 0.84 MAOB (0.53) SLC28A3MAOBSLC5A1PTPN1SYNJ2
SCHEMBL940116 0.80 SLC28A3 (0.81) SLC28A3SLC5A1PTPN1HIF1AKDM4E
SCHEMBL24063904 0.76 TYR (0.50) MAOB
SCHEMBL24425323 0.75 TYR (0.52) MAOB
SCHEMBL941509 0.75 MAOB (0.58) SLC28A3MAOBNPC1RAB9AL3MBTL1
SCHEMBL943278 0.75 MAOB (0.58) SLC28A3MAOBSLC5A1KDM4EMAPT
SCHEMBL3636327 0.75 MAOB (0.70) MAOBSLC5A1SYNJ2KDM4EABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110014141-A1 TOPICAL AGENT FOR DERMATOLOGICAL USE DSM IP ASSETS B.V. (NL) 2011-01-20 US disclosed
EP-1859835-A2 Topical agent for dermatological use containing 4-hydroxyphenyl-alpha-D-glucopyranoside PENTAPHARM Ltd. (CH) 2007-11-28 EP disclosed
US-20030198610-A1 Topical agent for dermatological use DSM IP ASSETS B.V. (NL) 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110014141-A1 TOPICAL AGENT FOR DERMATOLOGICAL USE GALE, ALPP, UGGT1 SLC28A3 2245/4885MAOB 301/4885SLC5A1 1371/4885
US-20030198610-A1 Topical agent for dermatological use GALE, UGGT1, UGDH SLC28A3 2040/4885MAOB 304/4885SLC5A1 1242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.